Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Cuzin L, Trabelsi S, Delobel P, Barbuat C, Reynes J, Allavena C, Peytavin G, Ghosn J, Lascoux-Combe C, Psomas C, Corbeau P, Flandre P; ANRS 145 MARIMUNO Study group. Cuzin L, et al. Among authors: flandre p. J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):557-64. doi: 10.1097/QAI.0b013e318273015f. J Acquir Immune Defic Syndr. 2012. PMID: 22986949 Clinical Trial.
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Descamps D, et al. Among authors: flandre p. JAMA. 2000 Jan 12;283(2):205-11. doi: 10.1001/jama.283.2.205. JAMA. 2000. PMID: 10634336 Clinical Trial.
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Yéni P; Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group. Launay O, et al. Among authors: flandre p. Clin Infect Dis. 2002 Nov 1;35(9):1096-105. doi: 10.1086/342694. Epub 2002 Oct 15. Clin Infect Dis. 2002. PMID: 12384844 Clinical Trial.
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D, Flandre P, Joly V, Meiffrédy V, Peytavin G, Izopet J, Tamalet C, Zeng AF, Harel M, Lastère S, Aboulker JP, Yéni P, Brun-Vézinet F; NOVAVIR (ANRS 073) Study Group. Descamps D, et al. Among authors: flandre p. J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):464-71. doi: 10.1097/00126334-200212150-00002. J Acquir Immune Defic Syndr. 2002. PMID: 12473833 Clinical Trial.
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Delaunay C, Brun-Vézinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D. Delaunay C, et al. Among authors: flandre p. J Virol. 2005 Aug;79(15):9572-8. doi: 10.1128/JVI.79.15.9572-9578.2005. J Virol. 2005. PMID: 16014919 Free PMC article. Clinical Trial.
163 results